Literature DB >> 14513344

[Therapeutic use of cannabinoids in neurology].

P Schwenkreis1, M Tegenthoff.   

Abstract

This review gives insight into the potential therapeutical role of cannabinoids in neurology. Preclinical data are presented which could give a rationale for the clinical use of cannabinoids in the fields of multiple sclerosis, spasticity, epilepsy, movement disorders, and neuroprotection after traumatic head injury or ischemic stroke. Besides, clinical data (case reports, open-label and randomised controlled studies) dealing with the therapeutical use of cannabinoids in these fields are reported and discussed. At present, clinical data are insufficient to recommend the use of cannabinoids in any neurological disease as standard therapy. Several questions still have to be answered (which cannabinoid? which way of administration? stimulation of endogenous cannabinoids? separation between desired and undesired effects?), and controlled studies are still needed to clarify the potential therapeutical role of cannabinoids in neurology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14513344     DOI: 10.1007/s00482-003-0240-z

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  58 in total

1.  Distribution of cannabinoid receptor messenger RNA in the human brain: an in situ hybridization histochemistry with oligonucleotides.

Authors:  P Mailleux; M Parmentier; J J Vanderhaeghen
Journal:  Neurosci Lett       Date:  1992-08-31       Impact factor: 3.046

2.  Nonpsychotropic cannabinoid acts as a functional N-methyl-D-aspartate receptor blocker.

Authors:  J J Feigenbaum; F Bergmann; S A Richmond; R Mechoulam; V Nadler; Y Kloog; M Sokolovsky
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

3.  Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis.

Authors:  A Achiron; S Miron; V Lavie; R Margalit; A Biegon
Journal:  J Neuroimmunol       Date:  2000-01-03       Impact factor: 3.478

4.  The effect of orally and rectally administered delta 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients.

Authors:  R Brenneisen; A Egli; M A Elsohly; V Henn; Y Spiess
Journal:  Int J Clin Pharmacol Ther       Date:  1996-10       Impact factor: 1.366

5.  An endogenous cannabinoid (2-AG) is neuroprotective after brain injury.

Authors:  D Panikashvili; C Simeonidou; S Ben-Shabat; L Hanus; A Breuer; R Mechoulam; E Shohami
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

6.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

7.  Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers.

Authors:  H S Greenberg; S A Werness; J E Pugh; R O Andrus; D J Anderson; E F Domino
Journal:  Clin Pharmacol Ther       Date:  1994-03       Impact factor: 6.875

8.  Cannabinoid receptor localization in brain.

Authors:  M Herkenham; A B Lynn; M D Little; M R Johnson; L S Melvin; B R de Costa; K C Rice
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

9.  Tetrahydrocannabinol for tremor in multiple sclerosis.

Authors:  D B Clifford
Journal:  Ann Neurol       Date:  1983-06       Impact factor: 10.422

10.  Cannabinoids control spasticity and tremor in a multiple sclerosis model.

Authors:  D Baker; G Pryce; J L Croxford; P Brown; R G Pertwee; J W Huffman; L Layward
Journal:  Nature       Date:  2000-03-02       Impact factor: 49.962

View more
  4 in total

Review 1.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

2.  Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model.

Authors:  Ming Zhang; Billy R Martin; Martin W Adler; Raj K Razdan; Jack I Jallo; Ronald F Tuma
Journal:  J Cereb Blood Flow Metab       Date:  2007-01-24       Impact factor: 6.200

Review 3.  Implication of cannabinoids in neurological diseases.

Authors:  Angela Alsasua del Valle
Journal:  Cell Mol Neurobiol       Date:  2006-05-12       Impact factor: 5.046

4.  [Respiratory failure due to delta-9-tetrahydrocannabinol in a tetraplegic patient].

Authors:  M Neuburger; M Schley; M Schmelz; G Schuepfer; C Konrad
Journal:  Schmerz       Date:  2006-11       Impact factor: 1.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.